CagriSema vs Tirzepatide: REDEFINE 4 and the Dose Question

CagriSema and tirzepatide have now been compared directly, but the answer depends on the trial. In the obesity study REDEFINE 4, CagriSema did not meet its primary goal of demonstrating noninferiority to tirzepatide. A later diabetes study, REIMAGINE 5, reported greater weight loss with a lower-dose CagriSema combination than with tirzepatide 5 mg. These are different comparisons, not contradictory verdicts.¹²

For someone considering treatment, the useful questions are which population was studied, which doses were compared and whether a medicine is available through an approved prescription. A headline percentage cannot answer all three.

What the medicines contain

CagriSema combines cagrilintide, an amylin analogue, with semaglutide, a GLP-1 receptor agonist. Tirzepatide acts at GIP and GLP-1 receptors. They therefore share one hormonal pathway but are different treatments.¹⁴

Novo Nordisk's September 30, 2026 announcement continued to describe CagriSema as investigational, with a U.S. application filed and an expected fourth-quarter decision. That is the latest dated sponsor status checked for this review; a projected decision is not an approval or a guaranteed launch date.³

Tirzepatide is the ingredient in Zepbound. Its current label includes long-term weight management for eligible adults and moderate to severe obstructive sleep apnea in adults with obesity. Eligibility and product choice still require clinical assessment.⁴

REDEFINE 4 compared higher doses in obesity

Novo's February 23 headline report describes 809 randomized participants, 84 weeks of treatment and an open-label design. Participants and investigators knew which treatment was given. The comparison was weekly CagriSema 2.4 mg/2.4 mg against tirzepatide 15 mg.¹

Two statistical approaches produced different numerical estimates. The analysis estimating effects if participants adhered to treatment reported 23.0% weight loss with CagriSema and 25.5% with tirzepatide. The treatment-regimen analysis, which addresses the assigned regimen including discontinuation, reported 20.2% and 23.6%, respectively. CagriSema failed the prespecified noninferiority objective.¹

Keep each pair together. Comparing 23.0% from one analysis with 23.6% from another hides the question each analysis was designed to answer. Failure to establish noninferiority also does not supply an individualized prediction for a person who has responded poorly to one medicine.

Why REIMAGINE 5 produced a different headline

On September 21, Novo reported a separate 60-week comparison in adults with type 2 diabetes inadequately controlled on metformin, an SGLT2 inhibitor or both. Here, the doses were CagriSema 1.0 mg/1.0 mg and tirzepatide 5 mg. The sponsor reported efficacy-estimand weight reductions of 12.4% and 9.1%, and HbA1c reductions of 1.71 and 1.67 percentage points; the glycemic result met noninferiority.²

This supports a conclusion about those doses in that diabetes population. It does not overturn the higher-dose obesity comparison, establish superiority over tirzepatide 15 mg, or establish a dose-conversion rule. Milligrams of different medicines are not interchangeable measures of biological effect.

What these reports cannot settle

The results above come from sponsor announcements, rather than a complete independently reviewed REDEFINE 4 publication retrieved for this review. The announcement describes gastrointestinal events as common with CagriSema but does not provide the full comparative safety tables needed to rank the treatments by tolerability.¹

We therefore do not infer a discontinuation advantage, long-term cardiovascular benefit or a preferred switching sequence. A future regulatory decision could also establish indications and prescribing instructions different from expectations during development.

Questions to take to your prescriber

Start with your diagnosis and current treatment response. Ask whether the comparison being discussed involved obesity or diabetes, whether it used your prescribed dose and what outcome matters most for you. Weight change, glucose control, adverse effects and continuity of access are separate considerations.

Do not recreate an investigational combination by adding semaglutide or research peptides to tirzepatide. Zepbound's label does not recommend using it with another GLP-1 receptor agonist.⁴ Our tirzepatide versus semaglutide guide and dosage chart explain approved-treatment comparisons; the zenagamtide guide covers a different investigational medicine.